Patents Assigned to Keio University
  • Patent number: 10934624
    Abstract: The aim of the present invention lies in inexpensively providing a thin-film laminated film having excellent barrier properties. A further aim of the present invention lies in providing a method for producing a thin-film laminated film in which a plurality of thin films are coated on a plastic film by means of atmospheric-pressure plasma CVD which has low equipment costs and running costs, and also in providing a thin-film laminated film production apparatus which is able to operate continuously for a long period of time and can produce high-speed coating. A thin film according to the present invention includes a plastic film, a first silicon oxide-based thin film containing silicon oxide as the main component, and a first amorphous carbon-based thin film. The first amorphous carbon-based thin film is formed on the first silicon oxide-based thin film. The first silicon oxide-based thin film has pinholes with a diameter in the range of 10-200 nm.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 2, 2021
    Assignees: Tetra Laval Holdings & Finance S.A., Keio University
    Inventors: Tetsuya Suzuki, Yuya Futagami, Akira Shirakura, Kazuya Ono
  • Publication number: 20210054330
    Abstract: An ultrasonic transducer (10) emits ultrasonic waves toward a culture solution (3) stored with cells (2) in a culture vessel (1). An acquirer acquires information indicating a settling state of the cells (2) in the culture solution (3). A controller controls an operation of the ultrasonic transducer (10) based on the information indicating the settling state of the cells (2).
    Type: Application
    Filed: July 5, 2018
    Publication date: February 25, 2021
    Applicants: Mitsubishi Electric Corporation, Keio University
    Inventors: Osamu TAKAHARA, Kazuhide KODEKI, Akira MORIKAWA, Tetsushi AZUMA, Kenjiro TAKEMURA, Yuta KURASHINA, Genichiro FUJII
  • Patent number: 10927401
    Abstract: A method for extracting substances from a fecal sample using mass spectrometry or nuclear magnetic resonance spectrometry, and metagenomic analysis using a next-generation sequencer.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: February 23, 2021
    Assignee: Keio University
    Inventors: Shinji Fukuda, Chiharu Ishii, Masaru Tomita
  • Patent number: 10919926
    Abstract: Problems of the present invention is to provide a novel compound or a salt thereof capable of activating natural killer T cell, a natural killer T cell activating agent containing such a compound or a salt thereof, and a pharmaceutical composition. The compound of the present invention is a compound represented by the following formula (1) or a salt thereof. It is preferable that total carbon number of the number of carbon atoms in the monovalent hydrocarbon group in R1 in the formula (1) excluding a sustitutent and the number of carbon atoms in the divalent hydrocarbon group in X1 is 5 to 50. The natural killer T cell activating agent contains the aforementioned compound or a salt thereof. The pharmaceutical composition contains the aforementioned compound or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 16, 2021
    Assignees: KEIO UNIVERSITY, REGiMMUNE CORPORATION
    Inventors: Shinsuke Inuki, Natsumi Hirata, Emi Kashiwabara, Junichiro Kishi, Toshihiko Aiba, Yukari Fujimoto
  • Publication number: 20210040445
    Abstract: A method for producing a tau-related disease model is provided. The method includes three-dimensionally culturing pluripotent stem cells having a mutation in a Microtubule Associated. Protein Tau (MAPT) gene to form a nerve organoid, and dissociating the nerve organoid into single cells and performing two-dimensional adherent culture to obtain neurons, in which the neurons are a tau-related disease model.
    Type: Application
    Filed: August 4, 2020
    Publication date: February 11, 2021
    Applicant: Keio University
    Inventors: Mari NAKAMURA, Seiji SHIOZAWA, Hideyuki OKANO
  • Patent number: 10912600
    Abstract: A high-frequency electrosurgical treatment instrument for operations, includes a pair of forceps pieces, an insulating member, a transmission member, a manipulation rod member, a distal end cover member, a shaft member and a manipulation portion. The instrument, includes a flow channel portion formed between the manipulation rod member and the shaft member, the flow channel portion being disposed along a longitudinal direction of the manipulation rod member to allow liquid to flow; a groove portion that communicates with the flow channel portion to allow the liquid to flow from the flow channel portion; and an opening portion that communicates with the groove portion to supply the liquid near the proximal end portions of the pair of forceps pieces.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: February 9, 2021
    Assignees: KEIO UNIVERSITY, OLYMPUS CORPORATION
    Inventors: Yuko Kitagawa, Minoru Tanabe, Norihiro Yamada
  • Publication number: 20210024887
    Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Applicant: KEIO UNIVERSITY
    Inventor: Minoru Ko
  • Patent number: 10901069
    Abstract: An activity recognition system for identification of an activity of a subject includes a transmitter configured to transmit a radio wave, a receiver configured to receive the radio wave by an array antenna, a feature quantity extracting part configured to extract a feature quantity from a signal received by the array antenna, and an identifying part configured to identify the activity based on the feature quantity, wherein the feature quantity extracting part is configured to calculate a first feature quantity that represents a change of the signal by using a signal received at an observation start time point as a reference signal and to calculate a second feature quantity that represents a change of the signal by using an immediately preceding signal as a reference signal, and the identifying part is configured to identify the activity based on the first feature quantity and the second feature quantity.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: January 26, 2021
    Assignee: Keio University
    Inventors: Tomoaki Otsuki, Yugo Agata
  • Publication number: 20200397826
    Abstract: Using the medium of the present invention for inducing a cornea endothelial substitute cell from an iPS cell, the medium containing an insulin-like growth factor and a STAT3 activator, and not containing a basic fibroblast growth factor or a ROCK inhibitor, and the method of the present invention for inducing corneal endothelial substitute cells from iPS cells by using the medium, it becomes possible to efficiently produce corneal endothelial substitute cells, particularly to efficiently produce corneal endothelial substitute cells from iPS cells. Furthermore, it becomes possible to stably produce large amounts of corneal endothelial substitute cells by inducing differentiation of iPS cells into corneal endothelial substitute cells more efficiently.
    Type: Application
    Filed: January 16, 2019
    Publication date: December 24, 2020
    Applicant: KEIO UNIVERSITY
    Inventors: Shigeto SHIMMURA, Shin HATOU, Kazuo TSUBOTA
  • Publication number: 20200383981
    Abstract: The disclosure provides a composition for inhibiting the growth and/or invasion of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression caused by cancer, or the like, which is characterized by being used for a specific subject.
    Type: Application
    Filed: June 29, 2018
    Publication date: December 10, 2020
    Applicant: Keio University
    Inventors: Nobuo Tsukamoto, Yutaka Kawakami
  • Publication number: 20200376681
    Abstract: Provided is technology for more appropriately realizing a human physical-act using a robot. This position/force control device comprises: an act time information retaining means for retaining a time interval or a time stamp of an act, in addition to act information when the act is recorded; a control reference information generation means for generating, from the recorded act information, information to serve as a control reference when the act is replicated; a control timing determination means for determining, from the recorded act time information, a timing for outputting the control reference information when the act is replicated; and a position/force control means for replicating the act on the basis of the generated control reference information and the determined control timing.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 3, 2020
    Applicants: KEIO UNIVERSITY, Motion Lib, Inc.
    Inventors: Kouhei OHNISHI, Takahiro NOZAKI, Takahiro MIZOGUCHI, Wataru IIDA
  • Patent number: 10836997
    Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: November 17, 2020
    Assignee: KEIO UNIVERSITY
    Inventor: Minoru Ko
  • Patent number: 10838408
    Abstract: A vibration control device moves an object by controlling an actuator. The vibration control device controls a position and speed of the actuator, generates a model by modeling the object; and calculates an inverse system output based on the model and the control to provide positive feedback of a position of the object based on the inverse system output.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: November 17, 2020
    Assignee: KEIO UNIVERSITY
    Inventors: Seiichiro Katsura, Eiichi Saito
  • Patent number: 10829523
    Abstract: The anti-tumor peptide provided by the present invention is a synthetic peptide having both amino acid sequences represented by the following (1) and (2): (1) an amino acid sequence constituting the transmembrane domain of transmembrane protein 141 (TMEM 141), or a modified amino acid sequence having deletion, replacement, or addition of one, two, or three amino acid residues of the amino acid sequence; and (2) an amino acid sequence functioning as a cell membrane penetrating peptide (CPP).
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 10, 2020
    Assignees: Keio University, National University Corporation Nagoya, Toagosei Co., Ltd.
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada, Jun Kudoh, Tamami Adachi, Yasuhiro Tonoyama
  • Publication number: 20200325453
    Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Applicants: ONO PHARMACEUTICAL CO., LTD., KEIO UNIVERSITY
    Inventors: Hideyuki OKANO, Seiji Shiozawa, Fumihiko Kisa
  • Publication number: 20200316027
    Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.
    Type: Application
    Filed: October 2, 2018
    Publication date: October 8, 2020
    Applicant: KEIO UNIVERSITY
    Inventors: Hideyuki SAYA, Oltea SAMPETREAN, Naoyoshi KOIKE, Nobuo KUBOTA
  • Publication number: 20200308621
    Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.
    Type: Application
    Filed: July 31, 2018
    Publication date: October 1, 2020
    Applicant: KEIO UNIVERSITY
    Inventors: Shigeto SHIMMURA, Shin HATOU, Emi INAGAKI, Kazuo TSUBOTA
  • Publication number: 20200297020
    Abstract: An object of the present invention is to provide means capable of exhibiting one or more of a physical strength improving effect and an anti-fatigue effect. The invention provides a composition containing Bacteroides uniformis or a treated product thereof, wherein the composition is used for improving one or more of physical strength and fatigue resistance.
    Type: Application
    Filed: September 25, 2018
    Publication date: September 24, 2020
    Applicants: Keio University, Asahi Group Holdings, Ltd.
    Inventors: Shinji FUKUDA, Chie KANO, Hiroto MORITA
  • Publication number: 20200283742
    Abstract: Provided are a method and a reagent for improving the activity of PETase. The method includes adding a surfactant, when a PETase (a) an aromatic polyester-degrading enzyme consisting of the amino acid sequence as set forth in SEQ ID NO: 2 or 4 in the sequence listing; or PETase (b) an aromatic polyester-degrading enzyme consisting of an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence as set forth in SEQ ID NO: 2 or 4 in the sequence listing, and having an aromatic polyester-degrading activity is allowed to act on PET so as to degrade the PET.
    Type: Application
    Filed: March 9, 2018
    Publication date: September 10, 2020
    Applicant: KEIO UNIVERSITY
    Inventors: Kenji MIYAMOTO, Makoto FURUKAWA, Norifumi KAWAKAMI, Kohei ODA
  • Publication number: 20200261476
    Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.
    Type: Application
    Filed: January 5, 2017
    Publication date: August 20, 2020
    Applicants: KEIO UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY, TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Hideyuki SAYA, Osamu NAGANO, Kenji TSUCHIHASHI, Kentaro SUINA, Nobuhiro NISHIYAMA, Hiroyasu TAKEMOTO, Takahiro NOMOTO, Makoto MATSUI, Keishiro TOMODA, Naoki YAMADA, Tsukasa NISHIMORI